You are here

  • Home
  • Archive
  • Volume 77, Issue 4
  • Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Authors

  1. Correspondence to Dr Ronald F van Vollenhoven, Department of Rheumatology, Amsterdam Rheumatology and immunology Center ARC, Amsterdam 1018 HV, The Netherlands; r.f.vanvollenhoven{at}amc.uva.nl
View Full Text

Citation

van Vollenhoven RF, Keystone EC, Strand V on behalf of the TREAT2b study team, et al
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
Annals of the Rheumatic Diseases 2018;77:495-499.

Publication history

  • Received October 2, 2017
  • Revised January 2, 2018
  • Accepted January 2, 2018
  • First published January 17, 2018.
Online issue publication 
October 31, 2019

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.